This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ghannoum, M. A.
Right arrow Articles by Galgiani, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghannoum, M. A.
Right arrow Articles by Galgiani, J. N.

Next Article 

Journal of Clinical Microbiology, Mar 1996, 489-495, Vol 34, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome

MA Ghannoum, JH Rex and JN Galgiani
Division of Infectious Diseases, Department of Internal Medicine, Harbor-University of California, Los Angeles, USA. ghannoum@humc.edu

In summary, it is clear that in vitro susceptibility testing can predict outcome in selected clinical situations. The clearest data are from the fluconazole-treated AIDS patients with oropharyngeal candidiasis. In this setting, the homogeneity of the underlying immune defect, combined with the ease of identification and monitoring of the infection, creates a near-perfect test situation. In more complex scenarios, such as the heterogeneous population of patients enrolled in a recent study of candidemia, no such clear-cut correlation was present. The importance of host factors in the correlation of the MIC with outcome cannot be overemphasized. Examples of these parameters include patient status (underlying disease, the presence of intravascular catheters, and CD4+ T-cell number), drug pharmacokinetics (absorption and distribution), patient compliance, and drug-drug interactions. Identification of relevant factors can substantially improve the degree of the MIC-outcome correlation and thus improve the clinical utility of in vitro testing. An important feature in this entire process is the role of standardized susceptibility testing procedures. While not without flaws, the proposed NCCLS reference method has been invaluable in allowing multiple investigators to contribute data that can be used to clarify the correlation between the fluconazole MIC and outcome. While the development of simplified second- generation methods is eagerly anticipated, the role of the reference method as a common touchstone is critical. Only by use of either the reference method itself or methods with a known relationship to the reference method can this broad collaborative process really proceed. Current work is focusing on defining interpretive breakpoints for fluconazole and Candida species, refinement of the in vitro procedures used to measure susceptibility to amphotericin B, ketoconazole, and itraconazole, and the acquisition of a broad base of data on the relationship between the MIC and outcome for these three drugs. Although considerable work remains to be done, the available data suggest that solutions to each of these problems are possible and that routine susceptibility testing of fungi will become meaningful for clinical decision making in the foreseeable future.


This article has been cited by other articles:

  • Rognon, B., Kozovska, Z., Coste, A. T., Pardini, G., Sanglard, D. (2006). Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 152: 3701-3722 [Abstract] [Full Text]  
  • van de Sande, W. W. J., Luijendijk, A., Ahmed, A. O. A., Bakker-Woudenberg, I. A. J. M., van Belkum, A. (2005). Testing of the In Vitro Susceptibilities of Madurella mycetomatis to Six Antifungal Agents by Using the Sensititre System in Comparison with a Viability-Based 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5- [(Phenylamino)Carbonyl]-2H-Tetrazolium Hydroxide (XTT) Assay and a Modified NCCLS Method. Antimicrob. Agents Chemother. 49: 1364-1368 [Abstract] [Full Text]  
  • Meletiadis, J., te Dorsthorst, D. T. A., Verweij, P. E. (2003). Use of Turbidimetric Growth Curves for Early Determination of Antifungal Drug Resistance of Filamentous Fungi. J. Clin. Microbiol. 41: 4718-4725 [Abstract] [Full Text]  
  • Nelson, S. M., Cartwright, C. P. (2003). Detection of Fluconazole-Resistant Isolates of Candida glabrata by Using an Agar Screen Assay. J. Clin. Microbiol. 41: 2141-2143 [Abstract] [Full Text]  
  • Hadley, S., Martinez, J. A., McDermott, L., Rapino, B., Snydman, D. R. (2002). Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J Antimicrob Chemother 49: 415-419 [Abstract] [Full Text]  
  • Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W. (2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev. 14: 643-658 [Abstract] [Full Text]  
  • Krcmery, V., Huttova, M., Mateicka, F., Laho, L., Jurga, L., Ondrusova, A., Tarekova, Z., Kralinsky, K., Hanzen, J., Liskova, A., Mrazova, M., Sabo, A., Pisarcikova, M., Kovacicova, G., Chovancova, D., Szovenyiova, Z. (2001). Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro. J Antimicrob Chemother 48: 521-525 [Abstract] [Full Text]  
  • Ramage, G., Vande Walle, K., Wickes, B. L., Lopez-Ribot, J. L. (2001). Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms. Antimicrob. Agents Chemother. 45: 2475-2479 [Abstract] [Full Text]  
  • Wenisch, C., Moore, C. B., Krause, R., Presterl, E., Pichna, P., Denning, D. W. (2001). Antifungal Susceptibility Testing of Fluconazole by Flow Cytometry Correlates with Clinical Outcome. J. Clin. Microbiol. 39: 2458-2462 [Abstract] [Full Text]  
  • Maebashi, K., Niimi, M., Kudoh, M., Fischer, F. J., Makimura, K., Niimi, K., Piper, R. J., Uchida, K., Arisawa, M., Cannon, R. D., Yamaguchi, H. (2001). Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J Antimicrob Chemother 47: 527-536 [Abstract] [Full Text]  
  • PINA-VAZ, C., SANSONETTY, F., RODRIGUES, A. G., COSTA-DE-OLIVEIRA, S., MARTINEZ-DE-OLIVEIRA, J., FONSECA, A. F. (2001). Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy. J Med Microbiol 50: 375-382 [Abstract] [Full Text]  
  • Marchetti, O., Majcherczyk, P. A., Glauser, M. P., Bille, J., Moreillon, P., Sanglard, D. (2001). Sensitive Bioassay for Determination of Fluconazole Concentrations in Plasma Using a Candida albicans Mutant Hypersusceptible to Azoles. Antimicrob. Agents Chemother. 45: 696-700 [Abstract] [Full Text]  
  • Mikamo, H., Sato, Y., Tamaya, T. (2000). In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 46: 485-487 [Abstract] [Full Text]  
  • Aller, A. I., Martin-Mazuelos, E., Lozano, F., Gomez-Mateos, J., Steele-Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F. J., Espinel-Ingroff, A. (2000). Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection. Antimicrob. Agents Chemother. 44: 1544-1548 [Abstract] [Full Text]  
  • Arthington-Skaggs, B. A., Motley, M., Warnock, D. W., Morrison, C. J. (2000). Comparative Evaluation of PASCO and National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Methods for Antifungal Drug Susceptibility Testing of Yeasts. J. Clin. Microbiol. 38: 2254-2260 [Abstract] [Full Text]  
  • Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., The SENTRY Participant Group, (2000). Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44: 747-751 [Abstract] [Full Text]  
  • Chang Chang, H., Jung Chang, J., Huey Huang, A., Chain Chang, T. (2000). Evaluation of a Capacitance Method for Direct Antifungal Susceptibility Testing of Yeasts in Positive Blood Cultures. J. Clin. Microbiol. 38: 971-976 [Abstract] [Full Text]  
  • Baran, J. Jr., Klauber, E., Barczak, J., Riederer, K., Khatib, R. (2000). Trends in Antifungal Susceptibility among Candida sp. Urinary Isolates from 1994 and 1998. J. Clin. Microbiol. 38: 870-871 [Abstract] [Full Text]  
  • Wirsching, S., Michel, S., Köhler, G., Morschhäuser, J. (2000). Activation of the Multiple Drug Resistance Gene MDR1 in Fluconazole-Resistant, Clinical Candida albicans Strains Is Caused by Mutations in a trans-Regulatory Factor. J. Bacteriol. 182: 400-404 [Abstract] [Full Text]  
  • Favre, B., Didmon, M., Ryder, N. S. (1999). Multiple amino acid substitutions in lanosterol 14{alpha}-demethylase contribute to azole resistance in Candida albicans. Microbiology 145: 2715-2725 [Abstract] [Full Text]  
  • Andes, D., van Ogtrop, M. (1999). Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model. Antimicrob. Agents Chemother. 43: 2116-2120 [Abstract] [Full Text]  
  • Martin-Mazuelos, E., Gutierrez, M. J., Aller, A. I., Bernal, S., Martinez, M. A., Montero, O., Quindos, G. (1999). A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.. J Antimicrob Chemother 43: 477-481 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • Fidel, P. L. Jr., Vazquez, J. A., Sobel, J. D. (1999). Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans. Clin. Microbiol. Rev. 12: 80-96 [Abstract] [Full Text]  
  • Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., Morschhäuser, J. (1998). Multiple Molecular Mechanisms Contribute to a Stepwise Development of Fluconazole Resistance in Clinical Candida albicans Strains. Antimicrob. Agents Chemother. 42: 3065-3072 [Abstract] [Full Text]  
  • Kirkpatrick, W. R., Turner, T. M., Fothergill, A. W., McCarthy, D. I., Redding, S. W., Rinaldi, M. G., Patterson, T. F. (1998). Fluconazole Disk Diffusion Susceptibility Testing of Candida Species. J. Clin. Microbiol. 36: 3429-3432 [Abstract] [Full Text]  
  • White, T. C., Marr, K. A., Bowden, R. A. (1998). Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin. Microbiol. Rev. 11: 382-402 [Abstract] [Full Text]  
  • Davey, K. G., Holmes, A. D., Johnson, E. M., Szekely, A., Warnock, D. W. (1998). Comparative Evaluation of FUNGITEST and Broth Microdilution Methods for Antifungal Drug Susceptibility Testing of Candida Species and Cryptococcus neoformans. J. Clin. Microbiol. 36: 926-930 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»